1 The impact of blinding on trial results: A systematic review and meta-

2 analysis

	_		
1		1	
	-		
		,	
٠	-	,	

4	Tyler Pitre
5	Department of Medicine, McMaster University, Hamilton, ON
6	Sarah Kirsh
7	Department of Anesthesia, McMaster University, Hamilton, ON
8	Tanvir Jassal
9	Department of Anesthesia, McMaster University, Hamilton, ON
10	Mason Anderson
11	Faculty of Health Sciences, McMaster University, Hamilton, ON
12	Adelia Padoan
13	Faculty of Health Sciences, McMaster University, Hamilton, ON
14	Alexander Xiang
15	Faculty of Health Sciences, McMaster University, Hamilton, ON
16	Jasmine Mah
17	Department of Medicine, Dalhousie University, Halifax, NS
18	Dena Zeraatkar*
19	Department of Anesthesia; Department of Health Research Methods, Evidence, and Impact, McMaster University,
20	Hamilton, ON
21	
22	
23	*Corresponding author:
24	Conflicts of interest: None.
25	Funding: None.
26	Data: Data available at https://osf.io/qb23h/.
27	Acknowledgements: None.
28	Authors' Contributions: DZ conceived the study. JM performed the search. SK, TJ, MA, AP, AX screened
29	studies and collected data. SK, TSP, and DZ wrote the manuscript. All authors reviewed and approved
30	the final version of the manuscript.

31 Word count: 3,584.

33 Abstract

34 **Background:** Blinding—the concealment of the arm to which participants have been randomized—is an

important consideration for assessing risk of bias of randomized trials. A growing body of evidence has,

36 however, yielded inconsistent results on whether trials without blinding produce biased findings.

37 **Objective:** To conduct a systematic review and meta-analysis of the evidence addressing whether trials

38 with and without blinding produce different results.

39 Methods: We searched MEDLINE, EMBASE, Cochrane Reviews, JBI EBP, and Web of Science, from

40 inception to May 2022, for studies comparing the results of trials with and without blinding. Pairs of

41 reviewers, working independently and in duplicate, reviewed search results for eligible studies and

42 extracted data.

43 We pooled the results of studies comparing trials with and without blinding of patients, healthcare

44 providers/investigators, and outcome assessors/adjudicators using frequentist random-effects meta-

45 analyses. We coded study results such that a ratio of odds ratio (ROR) < 1 and difference in standardized

46 mean difference (dSMD) < 0 indicate that trials without blinding overestimate treatment effects.

47 **Results:** We identified 47 eligible studies. For dichotomous outcomes, we found low certainty evidence

48 that trials without blinding of patients and healthcare providers, outcome assessors/adjudicators, and

49 patients may slightly overestimate treatment effects. For continuous outcomes, we found low certainty

50 evidence that trials without blinding of outcome assessors/adjudicators and patients may slightly

51 overestimate treatment effects.

52 **Conclusion:** Our systematic review and meta-analysis suggests that blinding may influence trial results in

53 select situations—albeit the findings are of low certainty and the magnitude of effect is modest. In the

54 absence of high certainty evidence suggesting that trials with and without blinding produce similar

results, investigators should be cautious about interpreting the results of trials without blinding.

56

57 Background

- 58 Randomized trials represent the optimal design for assessing the effectiveness of interventions.
- 59 Randomization ensures—more or less—that important known and unknown prognostic factors are
- 60 balanced between arms such that any observed differences between trial arms can be attributed to the
- 61 intervention under study. For decades, blinding—the concealment of the arm to which participants have
- 62 been randomized—has been an important consideration for assessing risk of bias of randomized trials
- 63 (1, 2).
- 64 Blinding of participants and healthcare providers reduces opportunity for differences in care (co-
- 65 interventions)—referred to as performance bias—whereas blinding of outcome assessors/adjudicators
- reduces differences in the measurement and adjudication of outcomes between trial arms—called
- 67 ascertainment bias (3, 4). Preconceived notions about the efficacy and safety of interventions, even
- 68 subconsciously, may theoretically impact decisions about co-interventions and outcome expectancy (5,
- 69 6).
- 70 Though there are clear advantages to blinding, blinding requires significant resources, increases the
- operational complexity of trials, and may not always be feasible. Funding and research organizations
- have invested in several initiatives to streamline and simplify clinical trials, and foregoing blinding is a
- 73 logical step in this process (7-9). It is unclear, however, the extent to which open-label trials may
- 74 produce biased findings.
- 75 Meta-epidemiologic studies (studies that analyze the results of previous studies to address how
- 76 methodological characteristics of the studies influence their results) have yielded inconsistent findings
- 77 (10-15). In this systematic review and meta-analysis, we summarize evidence addressing the effects of
- 78 blinding on trial results.

79 Methods

- 80 We registered a protocol on Open Science Framework (https://osf.io/qenky) on June 9, 2022. We report
- 81 our systematic review using the PRISMA reporting guidelines and guidelines for reporting meta-
- 82 epidemiologic methods studies (16, 17).

83 Search strategy

- 84 In consultation with an experienced research librarian, we searched MEDLINE, EMBASE, the Cochrane
- 85 Database of Systematic Reviews, JBI EBP, and Web of Science, from inception to May 2022, for studies
- 86 comparing the results of trials with and without blinding. We supplemented our search by reviewing the

87 reference lists of eligible studies. We did not restrict the search by date or language of publication.

88 Supplement 1 presents our search strategy.

89 Screening and study eligibility

- 90 Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers, working
- 91 independently and in duplicate, reviewed titles and abstracts of search records and subsequently the
- 92 full-texts of records deemed potentially eligible at the title and abstract screening stage. Reviewers
- resolved discrepancies by discussion, or, when necessary, by adjudication by a third party.
- 94 We included meta-epidemiologic studies that compared the results of trials in which either patients,
- 95 healthcare providers, outcome assessors/adjudicators, analysts, or manuscript writers were blinded to
- 96 trials in which either of these parties were not blinded. We included studies that investigated the effects
- 97 of blinding for trials addressing the effectiveness or safety of a treatment or management strategy and
- 98 excluded studies that investigated the effects of blinding in diagnostic studies. We did not restrict
- 99 eligibility based on the population, intervention, or outcomes or by language or date of publication.
- 100 We excluded single systematic reviews and meta-analyses that presented subgroup or sensitivity
- 101 analyses addressing blinding because single reviews are unlikely to provide precise estimates and
- 102 because such estimates have limited generalizability. We excluded conference abstracts and studies
- addressing the effects of blinding in animal studies or *in vitro* studies.

104 Data extraction and risk of bias assessments

- Pairs of reviewers, working independently and in duplicate, collected data and assessed the risk of biasof eligible studies.
- 107 We collected data on study characteristics (clinical condition, number of reviews/meta-analyses and
- 108 trials included, type of outcome investigated), blinding characteristics (blinding status of participants,
- 109 healthcare providers/investigators, outcome assessors/adjudicators, or other parties), and the results
- 110 for studies with and without blinding from the least and most adjusted estimate. For studies in which
- 111 multiple adjusted estimates were presented, based on previous evidence that the effects of blinding
- 112 may be confounded by allocation concealment, we preferentially extracted the estimate that was
- adjusted for allocation concealment (10, 18).
- 114 When reported, we extracted results separately for objective and subjective outcomes. We considered
- outcomes objective if they were established laboratory measures and other outcomes not subject to

interpretation (e.g., all-cause mortality, hospitalization) and subjective if outcomes were patient-

117 reported or subject to interpretation from healthcare providers or investigators (e.g., adverse events).

118 To our knowledge, there are no risk of bias tools for meta-epidemiologic studies. We assessed the risk of

- bias of eligible studies using ad-hoc criteria: selection bias (association between trial characteristics and
- 120 outcomes in trials selected for analysis), confounding (distortion of the effect of blinding on study results
- due to the correlation of the study characteristic of interest with other study characteristics that
- 122 influence the results), bias in classification of trial characteristics (misclassification of blinding status),
- bias in measurement of outcomes (errors in extraction or reporting of results that may be related to
- blinding), and selective reporting bias (selective reporting of study results based on the magnitude,
- statistical significance, or direction of findings). To make judgements about confounding bias, we

126 considered whether the study adjusted for allocation concealment, which has been shown to influence

127 trial results (10, 18), and to make judgements about bias in classification of trial characteristics and

measurement of outcomes, we considered the criteria used by the study to ascertain blinding status and

129 whether trial characteristics and outcome data were collected independently and in duplicate to reduce

130 the potential for errors (15, 19).

131 We rated risk of bias criteria as either low, probably low, probably high, or high risk of bias and

- 132 considered results at low risk of bias overall if all domains were rated as either low or probably low risk
- 133 of bias.

134 Reviewers resolved discrepancies by discussion or, when necessary, by third-party adjudication.

135 Data synthesis and analysis

136 We report categorical trial characteristics as proportions and percentages and continuous characteristics

as medians and interquartile ranges (IQRs). We synthesize the results of studies that compared trials

138 with and without blinding of patients and healthcare providers/investigators (corresponding to 'double-

139 blind') (20), outcome assessors/adjudicators, patients, healthcare providers/investigators, statisticians,

- 140 and manuscript writers.
- 141 We performed a frequentist random-effects meta-analysis with the restricted maximum likelihood
- 142 (REML) heterogeneity estimator to pool the results of studies. For studies that addressed dichotomous
- outcomes, we present results as ratios of odds ratios (ROR) and for studies that addressed continuous
- 144 outcomes, we present differences in standardized mean differences (dSMD) with the associated

- 145 confidence intervals. We recoded the data such that ROR < 1 and dSMD < 0 correspond to an
- 146 exaggerated effect in trials without blinding compared to trials with blinding.
- 147 Where possible, we meta-analyzed the least and most-adjusted results from primary studies. For studies
- 148 that converted dichotomous outcome measures to continuous outcome measures, or vice versa, we
- 149 combined them in analyses with the measure to which they were converted. When studies reported
- 150 multiple outcomes, we synthesized results for the outcome reported by the greatest number of trials.
- 151 We summarize heterogeneity using the l^2 statistic. We considered heterogeneity of 0%–40% as
- 152 potentially unimportant, 30%–60% as moderate, 50%–90% as substantial and 75%–100% as critical (21).
- 153 For analyses with 10 or more studies, we assessed for publication bias using funnel plots and the Egger's
- 154 test (22).

155 We performed all analyses in R (version 4.03, R Foundation for Statistical Computing), using the *meta*

and *metafor* packages. Open Science Framework (https://osf.io/qb23h/) presents the data and code to

- 157 generate the results in this study.
- 158 Where meta-analysis is not possible, we report the range and distribution of results from primary 159 studies (23).

160 Assessment of the certainty of evidence and interpretation of study results

161 We use a modified GRADE approach to assess the certainty of evidence (24). While GRADE has not been

developed to assess the certainty of meta-epidemiologic evidence, we anticipate that GRADE criteria are

- 163 still relevant to methodologic questions and meta-epidemiologic studies.
- 164 The GRADE approach rates the evidence as either high, moderate, low, or very low certainty based on
- 165 considerations of risk of bias (study limitations), inconsistency (heterogeneity in study results),
- 166 indirectness (differences between the questions addressed in studies and the question of interest),
- 167 publication bias (the tendency for studies with statistically significant results or positive results to be
- 168 published, published faster, or published in journals with higher visibility), and imprecision (random
- 169 error).
- 170 High certainty evidence indicates situations in which we are confident that the estimated effect
- 171 represents the true effect, and low or very low certainty evidence indicates situations in which the
- estimated effect may be substantially different from the true effect.

- 173 We considered an ROR of 1.10 or 0.90 and a dSMD of 0.1 to indicate minimally important effects of
- blinding on trial results, which was informed by our experiences in differences in effect estimates that
- 175 may influence decision-making (25, 26). Such an effect corresponds to a 10% difference in the results of
- 176 blinded and unblinded trials for dichotomous outcomes and a quarter standard deviation difference for
- 177 continuous outcomes.
- 178 We report our results using GRADE guidance (27), which involves describing the effect of an intervention
- based on the certainty of evidence (i.e., high certainty evidence the exposure is effective, moderate
- 180 certainty evidence the exposure is probably effective, low certainty evidence the exposure may be
- 181 effective and very low certainty evidence the effect of the exposure is unclear).
- 182 Results

183 Search results

- 184 Our search yielded a total of 6,623 unique records, of which 47 were eligible to be included (18, 28-73).
- 185 Figure 1 presents the results of the search and screening.

186 Study characteristics

- 187 Table 1 and Supplement 2 present study characteristics. Typical studies sampled meta-analyses and
- 188 compared the results of trials with and without blinding using either frequentist meta-regression or
- 189 Bayesian hierarchical models (74, 75). Studies that used frequentist meta-regressions compared the
- results of trials with and without blinding within each meta-analysis using meta-regression and then
- 191 pooled the results of coefficients corresponding to blinding across meta-analyses.
- A minority of studies reported on studies that made within trial comparisons (37, 38, 50-52). Such
- 193 studies included trials in which patients were randomized to blinded or open-label substudies or studies
- 194 that performed both blinded and open-label assessment of outcomes.
- 195 Studies included a median of 26 meta-analyses and 150 trials.

196 *Risk of bias assessments*

- 197 Figure 2 presents the risk of bias of studies that were included in the analysis investigating the effects of
- 198 blinding of patients and healthcare providers/investigators and Supplement 3 presents risk of bias
- 199 judgements for all studies.
- All studies were rated at high risk of bias, primarily due to confounding and selective reporting bias.
- 201 Studies seldom adjusted for allocation concealment and registered or published their protocols.

202 Blinding of patients and healthcare providers/investigators

- Twenty-four studies addressed the effects of blinding of patients and healthcare providers/investigators
 on trial results (18, 28, 29, 32, 36, 39, 40, 43-46, 49, 50, 54-56, 58-60, 64-66, 69). Table 2 presents the
- 205 results of our analyses.
- For dichotomous outcomes, we meta-analyzed seven studies, including 29546 meta-analyses and 3,732
- trials, and found evidence that trials without blinding of patients and healthcare providers may
- 208 overestimate dichotomous outcomes (low certainty due to risk of bias and imprecision) (Supplement 4).
- 209 When we restricted our analysis to studies that reported adjusted effect estimates, we found a smaller
- 210 difference between the results of trials with and without blinding.
- 211 For continuous outcomes, we meta-analyzed four studies, including 45 meta-analyses and 696 trials,
- and found that trials without blinding may not produce different results compared to trials with blinding
- 213 (low certainty due to risk of bias and imprecision).

214 Blinding of outcome assessors

- Twenty-three studies addressed the effects of blinding of outcome assessors/adjudicators (30, 33-35,
- 216 37-39, 41, 42, 44, 51-53, 55, 57, 58, 61-63, 71-73).
- For dichotomous outcomes, we meta-analyzed 12 studies, including 119 meta-analyses and 1,579 trials,
- and for continuous outcomes, we meta-analyzed 7 studies, including 78 meta-analyses and 1,426 trials,
- and found evidence that trials without blinding of outcome assessors may overestimate results (low
- 220 certainty due to risk of bias and imprecision). We found similar results when we restricted our analyses
- to subjective outcomes. For dichotomous outcomes, the funnel plot showed some evidence of
- asymmetry but the Egger test for funnel plot asymmetry was not statistically significant (p=0.38).

223 Blinding of patients

- Twelve studies addressed the effects of blinding of patients (31, 33-35, 41, 44, 47, 48, 55, 62, 71, 73).
- For dichotomous outcomes, we meta-analyzed four studies, including 78 meta-analyses and 1,106 trials
- and for continuous outcomes, we meta-analyzed seven studies, including 50 meta-analyses and 1,114
- trials. We found evidence that trials without blinding of patients may overestimate treatment effects
- 228 (low certainty due to risk of bias and imprecision). The results were similar when we restricted the
- analysis to subjective outcomes.

230 Blinding of healthcare providers/investigators

Nine studies addressed the effects of blinding of healthcare providers (33-35, 41, 44, 55, 63, 71, 73).

- 232 We meta-analyzed four studies reporting on dichotomous outcomes, including 54 meta-analyses and
- 233 902 trials, and four studies reporting on continuous outcomes, including 18 meta-analyses and 859
- trials. For both dichotomous and continuous outcomes, we found that trials without blinding of
- 235 healthcare providers may not overestimate treatment effects (low certainty due to risk of bias and
- 236 imprecision).

237 Statisticians and manuscript writers

- 238 Two studies addressed the effects of blinding of statisticians, one of which did not find sufficient data,
- and none of the studies addressed the effects of blinding of manuscript writers (34, 55).
- 240 The one study with data addressing the effects of blinding of statisticians found that blinding of
- statisticians may have no effect on trial results but that the results are very uncertain (very low certainty
- 242 due to risk of bias, imprecision, and indirectness).

243 Discussion

244 Main findings

- 245 Our systematic review presents evidence that trials without blinding may overestimate treatment
- effects—albeit the findings are of low certainty and the magnitude of effect is modest.
- 247 We found inconsistencies in the effects of blinding. While we found evidence, for example, that trials
- 248 without blinding of patients and healthcare providers may overestimate dichotomous outcomes, we did
- not find evidence for such an effect for continuous outcomes. Similarly, we also found inconsistencies
- across studies. The MetaBLIND study, for example, did not find evidence that trials with and without
- 251 blinding produce different results—contrary to several other studies of similar magnitude included in
- our review (40, 41, 59, 69). Further, studies that compared the effects of blinding within rather than
- across trials showed blinding to have larger effects (38, 50-52).
- Theoretical considerations about blinding may explain some of the observed inconsistencies. For
 example, we anticipate several factors that may vary based on the question being investigated and that
- 256 may influence the effect of blinding: investigators' and patients' preconceived notions about the
- 257 effectiveness of the intervention; whether there are co-interventions that may influence the outcome of
- interest; the magnitude of effect of the co-interventions on the outcome of interest; the potential for
- imbalances in the administration of co-interventions; and the degree of interpretation involved in
- assessment of outcomes (18, 76).

- An open-label trial addressing a condition for which there are no effective co-interventions or a trial in
- which healthcare providers and patients either do not have access to co-interventions or in which the
- administration of co-interventions is strictly regimented across arms is unlikely to be at risk of
- 264 performance bias. Similarly, an open-label trial addressing outcomes that are objective and not subject
- to interpretation is unlikely to be at risk of ascertainment bias.
- 266 In the absence of high certainty evidence suggesting that trials with and without blinding produce
- similar results, investigators should still be cautious about open-label trials.

268 Strengths and limitations

269 The strengths of our systematic review include *a priori* methods, a systematic search for eligible studies,

270 duplicate screening and data extraction, and assessment of the role of blinding across a range of clinical

- areas. Our review improves on previous reviews by performing an assessment of risk of bias and the
- 272 certainty of evidence and including several recently published studies not included in previous reviews

273 (10, 15, 18, 19, 33, 40, 44).

274 Our results are limited by the risk of bias of primary studies. Nearly all studies were rated at high risk of 275 bias, primarily due to potential for confounding and selective reporting bias. There is also potential for 276 misclassification of blinding status. A substantial proportion of trials, for example, did not explicitly 277 report the blinding status for all relevant parties (77). When trials did not explicitly report blinding 278 status, studies either used validated guidance to ascertain blinding status or grouped unblinded studies 279 with studies with unclear blinding (78). Even when blinding status was reported, the reporting may not 280 have been accurate (79). Several studies used the risk of bias judgements from meta-analyses as a 281 surrogate for blinding status, which may also contain errors or may reflect reviewers' judgements 282 regarding the potential impact of blinding or lack thereof on results rather than whether the trial was 283 blinded. This potential for misclassification means that the role of blinding may be more important than 284 our estimates suggest.

Our results are further limited by the potential inconsistency in the direction of the effect of blinding. While we anticipate that trials without blinding overestimate the beneficial effects of treatments, it is possible that the direction of bias caused by lack of blinding may not be consistent. That is, in certain circumstances open-label trials may overestimate effects and in other circumstances they may underestimate effects.

290 All of our analyses produced results that were imprecise. Further, our estimated effects for blinding

291 were generally small and evidence users may consider such effects too small to influence decision-

292 making, though most medical treatments show modest effects and hence even small biases may impact

293 decision-making (80, 81).

294 Trials addressing questions that are sensitive to performance bias and ascertainment bias may be more

likely to be blinded, thus reducing observed differences between trials with and without blinding.

296 There may be overlap between trials and meta-analyses included in meta-epidemiologic studies. An

inspection of the search strategies and clinical areas addressed by the included studies, however,

suggests that this overlap is likely minimal. To reduce the potential for double-counting, when meta-

299 epidemiologic studies reported more than one estimate that would be eligible to be included in each

analysis, we only included the estimate from the analysis that included the greatest number of trials.

301 While we tried to pool studies addressing the effects of blinding different individuals together (e.g.,

patients, healthcare providers), the ways in which types of blinding were defined and operationalized

303 across studies may have been slightly different.

304 It is possible that blinding may be compromised during a trial (e.g., due to obvious adverse events,

305 poorly matched placebos, or large therapeutic effects), which may have attenuated the difference

306 between trials with and without blinding.

307 Implications

The results of our systematic review have implications for evidence users who are appraising and applying evidence from open-label trials, for clinical trialists considering the potential benefits and burdens of implementing blinding in their clinical trials, and for global efforts to streamline and simplify clinical trial methods (7-9).

Results from the MetaBLIND study encouraged a critical evaluation of the importance of blinding in clinical trials (41). The study, for example, led to a revision of the Cochrane-endorsed risk of bias tool (RoB 2.0) to include a more nuanced approach for assessing bias due to lack of blinding (76). Results from MetaBLIND, however, were imprecise and were consistent with lack of blinding resulting in both an over- and underestimation of treatment effects. Further, there is no evidence whether the new approach to risk of bias assessments, proposed by the RoB 2.0 tool, that places less emphasis on blinding is better correlated with trial results.

The imprecision in results across meta-epidemiologic studies may be driven by heterogeneity in the effects of blinding across trials. That is, in some situations trials without blinding may overestimate treatment effects. Our findings suggest that evidence users should be cognizant of the ways in which lack of blinding may bias trial results, that clinical trialists should be judicious in their decisions to forego blinding, and that evidence users should be cognizant of the ways in which results.

- Evidence users should be mindful that the inability to identify evidence of when and how blinding
- affects trial results does not mean that open-label designs are unbiased. In fact, our review shows
- evidence that trials without blinding may overestimate treatment effects.
- 328 The subject of blinding invites comparisons to judgements about the quality of evidence from non-
- randomized studies. Despite evidence that randomized trials and non-randomized studies produce
- 330 consistent results in many situations (82-84), we typically consider non-randomized studies to produce
- lower certainty evidence compared to randomized trials because evidence users are unable to
- 332 confidently distinguish between situations in which non-randomized studies produce trustworthy or
- untrustworthy results. Uncertainty about the effects of blinding may analogously demand always or
- almost always rating open-label studies at high risk of bias.
- We show that we need higher certainty evidence to determine when and how blinding affects trial
- results. Initiatives such as Studies Within a Trial (SWATs)—research studies embedded within a host trial
- to assess alternative ways of delivering or organizing a particular trial process—can help address this
- need (85). While incorporating SWATs within trials to study how blinding affects results may increase
- the costs of trials, such initiatives may prove cost-effective in the long term by simplifying and
- 340 streamlining future trials without compromising the trustworthiness of results.

341 Conclusion

- 342 Our systematic review and meta-analysis presents evidence that trials without blinding may
- 343 overestimate treatment effects—albeit the findings are of low certainty and the magnitude of effect is
- modest. In the absence of high certainty evidence suggesting that trials with and without blinding
- 345 produce similar results, investigators should be cautious about interpreting the results of trials without
- 346 blinding.

347 Tables

Table 1: Table of study characteristics

Type of comparison	
Between trials	41 (87.2%)
Within trials	6 (12.8%)
Type of blinding	
Patient and healthcare providers/investigators	19 (40.4%)
Outcome assessors/adjudicators	22 (46.8%)
Patients	12 (25.5%)
Healthcare providers	9 (19.1%)
Median [IQR] number of systematic reviews/meta-analyses	26 [15, 70]
Median [IQR] number of trials	166 [35, 385.5]
Analytic model	
Bayesian hierarchical	4 (8.5%)
Frequentist meta-regression/multilevel regression	31 (66%)
Meta-analysis of trials with and without blinding	3 (6.4%)
Type of outcome	
Dichotomous	33 (70.2%)
Continuous	22 (46.8%)
Funding	
Government	21 (44.7%)
Institutional	4 (8.5%)
Industry	1 (2.1%)
Not-for-profit	2 (4.3%)
None	12 (25.5%)
Not reported	9 (19.1%)

348

Table 2: Results

Dichotomous outcomes				
Type of blinding	Studies	MAs (Trials)	ROR (95% CI)	Certainty
Patients and healthcare	7	206 (2722)	0.00 (0.77 +- 1.05)	222
providers	/	296 (3732)	0.90 (0.77 to 1.05)	LOW (due to risk of hiss improvision)
Patients and healthcare	5	252 (3059)	0.93 (0.87 to 0.99)	Low
providers (adjusted)				(due to risk of bias, imprecision)
				??????
Outcome assessors/adjudicators	12	119 (1579)	0.82 (0.71 to 0.96)	Low
				(due to risk of bias, imprecision)
Outcome assessors/adjudicators	1	46 (397)		???????????????????????????????????????
(adjusted)			1.04 (0.88 to 1.22)	Very low
(aujusteu)				(due to risk of bias, imprecision x2)
Patients	4	641 (1011)	0.85 (0.76 to 0.96)	???????????????????????????????????????

				Low
				(due to risk of bias, imprecision)
				?????
Patients (adjusted)	1	18 (132)	0.91 (0.61 to 1.35)	Very low
				(due to risk of bias, imprecision x2)
Healthcare				? ? ? ?
providers linuestigators	4	54 (902)	0.92 (0.79 to 1.07)	Low
providers/investigators				(due to risk of bias, imprecision)
Healthcare				???????????????????????????????????????
providers/investigators	1	29 (173)	1.03 (0.68 to 1.56)	Very low
(adjusted)		, , ,	, , , , , , , , , , , , , , , , , , ,	(due to risk of bias, imprecision x2)

Type of blinding	Studies	MAs (Trials)	dSMD (95% Cl)	Certainty
Patients and healthcare providers	4	45 (696)	0 (-0.1 to 0)	222 Low
Patients and healthcare providers (adjusted)	1	35 trials	-0.2 (-0.5 to 0.1)	(due to risk of blas, imprecision x2) (due to risk of blas, imprecision x2)
Outcome assessors/adjudicators	9	90 (1511)	-0.1 (-0.2 to 0)	222 Low (due to risk of bias, imprecision)
Outcome assessors/adjudicators (adjusted)	0	NA	NA	222 Very low
Patients	7	50 (1017)	-0.1 (-0.4 to 0.1)	(due to risk of bias, imprecision 22)
Patients (adjusted)	1	14 (158)	0 (-0.2 to 0.2)	?
Healthcare providers/investigators	4	18 (853)	0 (-0.2 to 0.1)	② ② ② ② Low (due to risk of bias, imprecision)
Healthcare providers/investigators (adjusted)	2	18 (643)	0 (-0.2 to 0.3)	② ② ② ② Very low (due to risk of bias, imprecision x2)

dSMD: difference in standardized mean difference; ROR= ratio of odds ratio

 $ROR < 1 \ and \ difference \ dSMD < 0 \ indicate \ that \ trials \ without \ blinding \ overestimate \ treatment \ effects$

349

350 References

1. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359(9307):696-700.

2. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. Bmj. 2000;321(7259):504.

355 3. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane 356 Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

4. Karanicolas PJ, Farrokhyar F, Bhandari M. Practical tips for surgical research: blinding: who, what, when, why, how? Can J Surg. 2010;53(5):345-8.

3595.Nickerson RS. Confirmation Bias: A Ubiquitous Phenomenon in Many Guises. Review of General360Psychology. 1998;2(2):175-220.

361 6. Rosenthal R. On the social psychology of the psychological experiment: the experimenter's
 362 hypothesis as unintended determinant of experimental results. Am Sci. 1963;51:268-83.

363 7. Protas. 2022 [Available from: <u>https://protas.co.uk/</u>.

3648.Corneli A, Hallinan Z, Hamre G, Perry B, Goldsack JC, Calvert SB, et al. The Clinical Trials365Transformation Initiative: Methodology supporting the mission. Clin Trials. 2018;15(1_suppl):13-8.

366 9. Kelly D, Spreafico A, Siu LL. Increasing operational and scientific efficiency in clinical trials. Br J 367 Cancer. 2020;123(8):1207-8.

Moustgaard H, Clayton GL, Jones HE, Boutron I, Jørgensen L, Laursen DRT, et al. Impact of
 blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. Bmj.
 2020;368:I6802.

Anthon CT, Granholm A, Perner A, Laake JH, Møller MH. No firm evidence that lack of blinding
affects estimates of mortality in randomized clinical trials of intensive care interventions: a systematic
review and meta-analysis. J Clin Epidemiol. 2018;100:71-81.

Baiardo Redaelli M, Belletti A, Monti G, Lembo R, Ortalda A, Landoni G, et al. The impact of nonblinding in critical care medicine trials. J Crit Care. 2018;48:414-7.

Martin GL, Trioux T, Gaudry S, Tubach F, Hajage D, Dechartres A. Association Between Lack of
Blinding and Mortality Results in Critical Care Randomized Controlled Trials: A Meta-Epidemiological
Study. Crit Care Med. 2021;49(10):1800-11.

Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association Between
Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES MetaEpidemiologic Study. Am J Epidemiol. 2018;187(5):1113-22.

Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savović J. Empirical Evidence of Study
 Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies. PLoS One.
 2016;11(7):e0159267.

16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed).
2021;74(9):790-9.

Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid
Based Med. 2017;22(4):139-42.

390 18. Zeraatkar D, Pitre T, Diaz-Martinez JP, Chu D, Rochwerg B, Lamontagne F, et al. Effects of
 allocation concealment and blinding in trials addressing treatments for COVID-19: A methods study.
 medRxiv. 2022:2022.08.03.22278348.

39319.Dechartres A, Trinquart L, Faber T, Ravaud P. Empirical evaluation of which trial characteristics394are associated with treatment effect estimates. J Clin Epidemiol. 2016;77:24-37.

20. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician
 interpretations and textbook definitions of blinding terminology in randomized controlled trials. Jama.
 2001;285(15):2000-3.

21. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted
systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.
Cochrane Database Syst Rev. 2019;10:Ed000142.

401 22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 402 graphical test. Bmj. 1997;315(7109):629-34.

40323.Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without404meta-analysis (SWiM) in systematic reviews: reporting guideline. Bmj. 2020;368:16890.

405 24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging 406 consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.

407 25. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group 408 clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4-13.

26. Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE
Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol.
2022.

412 27. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: 413 informative statements to communicate the findings of systematic reviews of interventions. J Clin 414 Epidemiol. 2020;119:126-35.

415 28. Ioannidis JPA, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and
416 reporting of randomized clinical trials of HIV infection. Controlled Clinical Trials. 1997;18(5):431-44.

417 29. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between 418 large and small randomized trials in meta-analyses. Annals of Internal Medicine. 2001;135(11):982-9.

419 30. Liu CJ, LaValley M, Latham NK. Do unblinded assessors bias muscle strength outcomes in
420 randomized controlled trials of progressive resistance strength training in older adults? American journal
421 of physical medicine & rehabilitation / Association of Academic Physiatrists. 2011;90(3):190-6.

Nuesch E, Reichenbach S, Trelle S, Rutjes AWS, Liewald K, Sterchi R, et al. The importance of
allocation concealment and patient blinding in osteoarthritis trials: A meta-epidemiologic study. Arthritis
Care and Research. 2009;61(12):1633-41.

425 32. Schulz KF, Chalmers L, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of 426 methodological quality associated with estimates of treatment effects in controlled trials. Journal of the 427 American Medical Association. 1995;273(5):408-12.

428 33. Amer MA, Herbison GP, Grainger SH, Khoo CH, Smith MD, McCall JL. A meta-epidemiological 429 study of bias in randomized clinical trials of open and laparoscopic surgery. The British journal of 430 surgery. 2021;108(5):477-83.

431 34. Armijo-Olivo S, Fuentes J, da Costa BR, Saltaji H, Ha C, Cummings GG. Blinding in Physical
432 Therapy Trials and Its Association with Treatment Effects: A Meta-epidemiological Study. American
433 journal of physical medicine & rehabilitation. 2017;96(1):34-44.

Bolvig J, Juhl CB, Boutron I, Tugwell P, Ghogomu EAT, Pardo JP, et al. Some Cochrane risk-of-bias
items are not important in osteoarthritis trials: a meta-epidemiological study based on Cochrane
reviews. Journal of clinical epidemiology. 2018;95:128-36.

437 36. Cuijpers P, Karyotaki E, Andersson G, Li J, Mergl R, Hegerl U. The effects of blinding on the 438 outcomes of psychotherapy and pharmacotherapy for adult depression: A meta-analysis. European 439 psychiatry : the journal of the Association of European Psychiatrists. 2015;30(6):685-93.

37. Dello Russo C, Cappoli N, Pilunni D, Navarra P. Local Investigators Significantly Overestimate
Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials.
Journal of Clinical Pharmacology. 2021;61(6):810-9.

443 38. Hrobjartsson A, Emanuelsson F, Thomsen ASS, Hilden J, Brorson S. Bias due to lack of patient 444 blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-445 studies. International Journal of Epidemiology. 2014;43(4):1272-83.

446 39. Koletsi D, Spineli LM, Lempesi E, Pandis N. Risk of bias and magnitude of effect in orthodontic
447 randomized controlled trials: a meta-epidemiological review. European journal of orthodontics.
448 2016;38(3):308-12.

449 40. Martin GL, Trioux T, Gaudry S, Tubach F, Hajage D, Dechartres A. Association Between Lack of 450 Blinding and Mortality Results in Critical Care Randomized Controlled Trials: A Meta-Epidemiological

451 Study. Critical care medicine. 2021;49(10):1800-11.

452 41. Moustgaard H, Clayton GL, Jones HE, Boutron I, Jorgensen L, Laursen DLT, et al. Impact of 453 blinding on estimated treatment effects in randomised clinical trials: Meta-epidemiological study. The 454 BMJ. 2020;368:I6802.

42. Poolman RW, Struijs PAA, Krips R, Sierevelt IN, Marti RK, Farrokhyar F, et al. Reporting of 456 outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter? The Journal of 457 bone and joint surgery American volume. 2007;89(3):550-8.

43. Probst P, Zaschke S, Heger P, Harnoss JC, Huttner FJ, Mihaljevic AL, et al. Evidence-based recommendations for blinding in surgical trials. Langenbeck's archives of surgery. 2019;404(3):273-84.

46. Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, da Costa BR, Flores-Mir C. Influence of blinding
461 on treatment effect size estimate in randomized controlled trials of oral health interventions. BMC
462 medical research methodology. 2018;18(1):42.

463 45. Anthon CT, Granholm A, Pemer A, Laake JH, Moller MH. No firm evidence that lack of blinding
affects estimates of mortality in randomized clinical trials of intensive care interventions: a systematic
review and meta-analysis. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2018;100:71-81.

466 46. Baiardo Redaelli M, Belletti A, Monti G, Lembo R, Ortalda A, Landoni G, et al. The impact of non-467 blinding in critical care medicine trials. Journal of Critical Care. 2018;48:414-7.

468 47. Braithwaite FA, Walters JL, Li LSK, Lorimer Moseley G, Williams MT, McEvoy MP. Effectiveness 469 and adequacy of blinding in the moderation of pain outcomes: Systematic review and meta-analyses of 470 dry needling trials. PeerJ. 2018;2018(7):e5318.

48. Feys F, Bekkering GE, Singh K, Devroey D. Do randomized clinical trials with inadequate blinding
report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
Systematic Reviews. 2014;3(1):14.

474 49. Howard JP, Shun-Shin MJ, Hartley A, Bhatt DL, Krum H, Francis DP. Quantifying the 3 Biases That
475 Lead to Unintentional Overestimation of the Blood Pressure-Lowering Effect of Renal Denervation.
476 Circulation: Cardiovascular Quality and Outcomes. 2016;9(1):14-22.

477 50. Hrobjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Rasmussen JV, Hilden J, et al. Observer 478 bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both 479 blinded and non-blinded outcome assessors. International journal of epidemiology. 2014;43(3):937-48.

480 51. Hrobjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias
481 in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non482 blinded outcome assessors. BMJ (Clinical research ed). 2012;344:e1119.

483 52. Hrobjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias 484 in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both 485 blinded and nonblinded assessors. CMAJ : Canadian Medical Association journal = journal de 486 l'Association medicale canadienne. 2013;185(4):E201-11.

487 53. Ndounga Diakou LA, Trinquart L, Hrobjartsson A, Barnes C, Yavchitz A, Ravaud P, et al.
488 Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect
489 estimates. Cochrane Database of Systematic Reviews. 2016;2016(3):MR000043.

490 54. Trone JC, Chapelle C, Ollier E, Bertoletti L, Cucherat M, Mismetti P, et al. Statistical controversies
491 in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to
492 evaluation of vascular adverse drug events-a meta-analysis. Annals of Oncology. 2018;29(4).

493 55. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality
494 measures with estimates of treatment effect in meta-analyses of randomized controlled trials. Jama.
495 2002;287(22):2973-82.

496 56. Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, et al. Assessing the quality of reports
497 of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999;3(12):i498 iv, 1-98.

499 57. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-500 analysis. Jama. 1999;282(11):1054-60.

501 58. Lega JC, Mismetti P, Fassier T, Bertoletti L, Cucherat M, Vital-Durand D, et al. Double blind vs. 502 open design on treatment effect of new oral anticoagulants in atrial fibrillation: A meta-analysis. 503 Fundamental and Clinical Pharmacology. 2012;26(SUPPL.1):17.

504 59. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study 505 design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern 506 Med. 2012;157(6):429-38.

50760.Unverzagt S, Prondzinsky R, Peinemann F. Single-center trials tend to provide larger treatment508effects than multicenter trials: a systematic review. J Clin Epidemiol. 2013;66(11):1271-80.

509 61. Hartling L, Hamm MP, Fernandes RM, Dryden DM, Vandermeer B. Quantifying bias in 510 randomized controlled trials in child health: a meta-epidemiological study. PLoS One. 2014;9(2):e88008.

- 511 62. Chaimani A, Vasiliadis HS, Pandis N, Schmid CH, Welton NJ, Salanti G. Effects of study precision 512 and risk of bias in networks of interventions: a network meta-epidemiological study. Int J Epidemiol. 513 2013;42(4):1120-31.
- 514 63. Bialy L, Vandermeer B, Lacaze-Masmonteil T, Dryden DM, Hartling L. A meta-epidemiological 515 study to examine the association between bias and treatment effects in neonatal trials. Evid Based Child 516 Health. 2014;9(4):1052-9.
- 517 64. Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation 518 concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 519 2007;36(4):847-57.
- 520 65. Contopoulos-Ioannidis DG, Gilbody SM, Trikalinos TA, Churchill R, Wahlbeck K, Ioannidis JPA. 521 Comparison of Large Versus Smaller Randomized Trials for Mental Health-Related Interventions. 522 American Journal of Psychiatry. 2005;162(3):578-84.
- 523 66. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature 524 searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol 525 Assess. 2003;7(1):1-76.
- 526 67. Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable modelling for meta-527 epidemiological assessment of the association between trial quality and treatment effects estimated in 528 randomized clinical trials. Stat Med. 2007;26(14):2745-58.
- 529 68. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in 530 treatment effect estimates in controlled trials with different interventions and outcomes: meta-531 epidemiological study. Bmj. 2008;336(7644):601-5.
- 532 69. Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association Between 533 Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-534 Epidemiologic Study. American Journal of Epidemiology. 2017;187(5):1113-22.
- 53570.Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association Between Analytic536Strategy and Estimates of Treatment Outcomes in Meta-analyses. JAMA. 2014;312(6):623-30.
- 537 71. van Tulder MW, Suttorp M, Morton S, Bouter LM, Shekelle P. Empirical evidence of an 538 association between internal validity and effect size in randomized controlled trials of low-back pain. 539 Spine (Phila Pa 1976). 2009;34(16):1685-92.
- 540 72. Fenwick J, Needleman IG, Moles DR. The effect of bias on the magnitude of clinical outcomes in 541 periodontology: a pilot study. J Clin Periodontol. 2008;35(9):775-82.
- 542 73. Hempel S, Miles J, Suttorp MJ, Wang Z, Johnsen B, Morton S, et al. AHRQ Methods for Effective
- Health Care. Detection of Associations Between Trial Quality and Effect Sizes. Rockville (MD): Agency for
 Healthcare Research and Quality (US); 2012.

545 74. Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC. Models for potentially biased evidence in
546 meta-analysis using empirically based priors. Journal of the Royal Statistical Society: Series A (Statistics
547 in Society). 2009;172(1):119-36.

548 75. Sterne JA, Jüni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the 549 influence of study characteristics on treatment effects in 'meta-epidemiological' research. Stat Med. 550 2002;21(11):1513-24.

551 76. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for 552 assessing risk of bias in randomised trials. BMJ. 2019;366:14898.

553 77. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the 554 reporting of blinding status in randomized controlled trials. J Clin Epidemiol. 2002;55(8):787-90.

- 555 78. Akl EA, Sun X, Busse JW, Johnston BC, Briel M, Mulla S, et al. Specific instructions for estimating 556 unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol. 557 2012;65(3):262-7.
- 558 79. Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and 559 a survey of authors. Clin Trials. 2006;3(4):360-5.

560 80. Kent DM, Trikalinos TA. Therapeutic innovations, diminishing returns, and control rate 561 preservation. Jama. 2009;302(20):2254-6.

- 562 81. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of 563 medical interventions. Jama. 2012;308(16):1676-84.
- 564 82. Janiaud P, Agarwal A, Tzoulaki I, Theodoratou E, Tsilidis KK, Evangelou E, et al. Validity of 565 observational evidence on putative risk and protective factors: appraisal of 3744 meta-analyses on 57 566 topics. BMC Med. 2021;19(1):157.
- 567 83. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study 568 designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 569 2014;2014(4):Mr000034.
- 57084.Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N571Engl J Med. 2000;342(25):1878-86.
- 572 85. Treweek S, Bevan S, Bower P, Campbell M, Christie J, Clarke M, et al. Trial Forge Guidance 1: 573 what is a Study Within A Trial (SWAT)? Trials. 2018;19(1):139.
- 574



C+udv	Voor	celectionbias	confounding	aiasinclassific	ation of trial char	acteristics	utcomes reporting bias
Study	Year 2015	7		V	V	7	
Hartling	2013						
Kolotsi	2014						Low risk of higs
Martin	2010						Probably low risk of hiss
Mohor	1000						Probably low risk of bias
Dildal	2007						High rick of bias
Saltaii	2007						
Savovic	2018						
Savovic	2012						
Schulz	1005						
Trope	2018						
Linvorzad	2010 + 2012						
Zoraatkar	2012						
	2022						